FOSUN PHARMA2196.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, FOSUN PHARMA (2196.HK) trades at a P/E of 11.80x, P/B of 1.18x, P/S of 0.94x, and a dividend yield of 2.64%.
Longitudinal percentile comparison: P/E sits at the 8th percentile over the trailing 10Y window (vs. 17th percentile over 3Y); P/B sits at the 4th percentile over the trailing 10Y window (vs. 13th percentile over 3Y); P/S sits at the 16th percentile over the trailing 10Y window (vs. 52nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 37th percentile within its industry and the 54th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 2.97%, ranking at the 99th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 3.9 points of each other — a consistent signal from both angles. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 2.97% total shareholder yield, 2.64% is paid out as dividends and roughly 0.33% is implied to come from buybacks — both channels are meaningfully in play. FOSUN PHARMA operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2196 · SEHK: 2196 · 2196
Want the full picture on whether FOSUN PHARMA (2196.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 11.80 | ||||||
| P/B (MRQ) | 1.18 | ||||||
| P/S (TTM) | 0.94 | ||||||
| Dividend Yield | 2.64% | ||||||
| Buyback + Div Yield | 2.97% |